With expanding insight into its involvement in islet regeneration and post-surgical metabolic adaptation, PYY has the potential to transition from an experimental satiety agent to an essential component of advanced diabetes therapies focused on restoring endocrine capacity and enabling lasting glycemic control. This evidence concerns the gene PYY and diabetes mellitus.